UK approves sotrovimab (Xevudy) as new Covid treatment for high risk adultsDecember 3, 2021
The Medicines and Healthcare Products Regulatory Agency (MHRA), the drug regulator of UK, has approved sotrovimab, branded as Xevudy, a new biological drug to fight Covid-19. The drug was found effective to reduce the likelihood of hospital admission and death by about 79 percent in high-risk adults.
A monoclonal antibody made by GlaxoSmithKline (GSK) and Vir Biotechnology, Xevudy is indicated for people with mild to moderate Covid-19 at high risk of developing severe disease.
GSK and Vir Biotechnology claimed that preclinical data showed the drug retains activity against key mutations of the new Omicron variant of coronavirus.
Xevudy is the second monoclonal antibody treatment to be approved by the MHRA . It had authorised Ronapreve, developed by Regeneron-Roche combine, in August. Following approval, the UK government has ordered about 100,000 doses of Xevudy.